Skip to main content

Advertisement

SpringerLink
Log in

Prostate cancer-related anxiety in long-term survivors after radical prostatectomy

  • Published:
Journal of Cancer Survivorship Aims and scope Submit manuscript

Abstract

Purpose

Knowledge of the psychological distress of long- and very long-term (>10 years) prostate cancer (PC) survivors is limited. This study intended to examine the parameters influencing anxiety related to prostate-specific antigen (PSA) and PC in long-term survivors after radical prostatectomy.

Methods

We surveyed 4719 PC survivors from the German multicenter prospective database “Familial Prostate Cancer.” We evaluated the association of PC-related anxiety (MAX-PC) with sociodemographic characteristics, family history of PC, global health status/quality of life (EORTC QLQ-C30), depression and anxiety (PHQ-2; GAD-2), latest PSA level, time since radical prostatectomy, and current therapy.

Results

The survey participants’ mean age was 75.2 years (SD = 6.5). Median follow-up was 11.5 years, and 19.5% of participants had survived more than 15 years since the initial treatment. The final regression analysis found that younger age, lower global health status/quality of life, higher depression and anxiety scores, higher latest PSA level, and shorter time since radical prostatectomy predicted increased PSA-related anxiety and PC anxiety. Familial PC was predictive only of PSA anxiety (all p < 0.05). The final model explained 12% of the variance for PSA anxiety and 24% for PC anxiety.

Conclusions

PC-related anxiety remained relevant many years after prostatectomy and was influenced by younger age, psychological status, rising PSA level, and shorter time since initial treatment.

Implications for Cancer Survivors

Survivors with these characteristics are at increased risk of PC-related anxieties, which should be considered by the treating physician during follow-up.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Zhou CK, Check DP, Lortet-Tieulent J, et al. Prostate cancer incidence in 43 populations worldwide: an analysis of time trends overall and by age group. Int J Cancer. 2016;138:1388–400.

    Article  CAS  PubMed  Google Scholar 

  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2016;66:7–30.

    Article  PubMed  Google Scholar 

  3. Robert Koch Institut. Krebs in Deutschland 2011/2012 [Cancer in Germany 2011/2012]. 10. Edition, 2015. http://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2015/krebs_in_deutschland_2015.pdf?__blob=publicationFile. Accessed 25 Nov 2016.

  4. Steinberg GD, Carter BS, Beaty TH, et al. Family history and the risk of prostate cancer. Prostate. 1990;17:337–47.

    Article  CAS  PubMed  Google Scholar 

  5. Powell IJ, Meyskens FL. African American men and hereditary/familial prostate cancer: intermediate-risk populations for chemoprevention trials. Urology. 2001;57:178–81.

    Article  CAS  PubMed  Google Scholar 

  6. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. SEER stat fact sheets: prostate cancer. 2015. http://seer.cancer.gov/statfacts/html/prost.html. Accessed 25 Nov 2016.

  7. Budäus L, Spethmann J, Isbarn H, et al. Inverse stage migration in patients undergoing radical prostatectomy: results of 8916 European patients treated within the last decade. BJU Int. 2011;108:1256–61.

    Article  PubMed  Google Scholar 

  8. World Health Organization. Life expectancy data by country. 2015. http://apps.who.int/gho/data/node.main.688. Accessed 25 Nov 2016.

  9. Lassemillante AC, Doi SA, Hooper JD, et al. Prevalence of osteoporosis in prostate cancer survivors: a meta-analysis. Endocrine. 2014;45:370–81.

    Article  CAS  PubMed  Google Scholar 

  10. Hyde MK, Zajdlewicz L, Wootten AC, et al. Medical help-seeking for sexual concerns in prostate cancer survivors. Sex Med. 2016;4:e7–e17.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Olsson CE, Alsadius D, Pettersson N, et al. Patient-reported sexual toxicity after radiation therapy in long-term prostate cancer survivors. Br J Cancer. 2015;113:802–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Kopp RP, Marshall LM, Wang PY, et al. The burden of urinary incontinence and urinary bother among elderly prostate cancer survivors. Eur Urol. 2013;64:672–9.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Gavin AT, Drummond JF, Donnelly C, et al. Patient-reported ‘ever had’ and ‘current’ long-term physical symptoms after prostate cancer treatments. BJU Int. 2015;116:397–406.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Darwish-Yassine M, Berenji M, Wing D, et al. Evaluating long-term patient-centered outcomes following prostate cancer treatment: findings from the Michigan Prostate Cancer Survivor study. J Cancer Surviv. 2014;8:121–30.

    Article  PubMed  Google Scholar 

  15. van de Wal M, van Oort I, Schouten J, et al. Fear of cancer recurrence in prostate cancer survivors. Acta Oncol. 2016;55:821–7.

    Article  PubMed  Google Scholar 

  16. Dahl S, Cvancarova M, Dahl AA, et al. Work ability in prostate cancer survivors after radical prostatectomy. Scand J Urol. 2016;50:116–22.

    Article  PubMed  Google Scholar 

  17. Morris BB, Farnan L, Song L, et al. Treatment decisional regret among men with prostate cancer: racial differences and influential factors in the North Carolina Health Access and Prostate Cancer Treatment Project (HCaP-NC). Cancer. 2015;121:2029–35.

    Article  PubMed  Google Scholar 

  18. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer. 2008;8:268–78.

    Article  CAS  PubMed  Google Scholar 

  19. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer. 2016. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 25 Nov 2016.

  20. European Association of Urology. Guidelines on prostate cancer. 2016. https://uroweb.org/guideline/prostate-cancer/. Accessed 25 Nov 2016.

  21. Shen MJ, Nelson CJ, Peters E, et al. Decision-making processes among prostate cancer survivors with rising PSA levels: results from a qualitative analysis. Med Decis Mak. 2015;35:477–86.

    Article  Google Scholar 

  22. Dale W, Bilir P, Han M, et al. The role of anxiety in prostate carcinoma. Cancer. 2005;104:467–78.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Klotz LH. PSAdynia and other PSA-related syndromes: a new epidemic—a case history and taxonomy. Urology. 1997;50:831–2.

    Article  CAS  PubMed  Google Scholar 

  24. Punnen S, Cowan JE, Chan JM, et al. Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry. Eur Urol. 2015;68:600–8.

    Article  PubMed  Google Scholar 

  25. Watts S, Leydon G, Birch B, et al. Depression and anxiety in prostate cancer: a systematic review and meta-analysis of prevalence rates. BMJ Open. 2014;4:e003901.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Sharp L, O’Leary E, Kinnear H, et al. Cancer-related symptoms predict psychological wellbeing among prostate cancer survivors: results from the PiCTure study. Psycho-Oncology. 2016;25:282–91.

    Article  PubMed  Google Scholar 

  27. Dinkel A, Kornmayer M, Gschwend JE, et al. Influence of family history on psychosocial distress and perceived need for treatment in prostate cancer survivors. Familial Cancer. 2014;13:481–8.

    Article  PubMed  Google Scholar 

  28. Tavlarides AM, Ames SC, Diehl NN, et al. Evaluation of the association of prostate cancer-specific anxiety with sexual function, depression and cancer aggressiveness in men 1 year following surgical treatment for localized prostate cancer. Psycho-Oncology. 2013;22:1328–35.

    Article  PubMed  Google Scholar 

  29. Roth A, Nelson CJ, Rosenfeld B, et al. Assessing anxiety in men with prostate cancer: further data on the reliability and validity of the Memorial Anxiety Scale for Prostate Cancer (MAX–PC). Psychosomatics. 2006;47:340–7.

    Article  PubMed  Google Scholar 

  30. Roth AJ, Rosenfeld B, Kornblith AB, et al. The Memorial Anxiety Scale for Prostate Cancer. Validation of a new scale to measure anxiety in men with prosate cancer. Cancer. 2003;97:2910–8.

    Article  PubMed  Google Scholar 

  31. Venderbos LD, van den Bergh RC, Roobol MJ, et al. A longitudinal study on the impact of active surveillance for prostate cancer on anxiety and distress levels. Psycho-Oncology. 2015;24:348–54.

    Article  PubMed  Google Scholar 

  32. Tan HJ, Marks LS, Hoyt MA, et al. The relationship between intolerance of uncertainty and anxiety in men on active surveillance for prostate cancer. J Urol. 2016;195:1724–30.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Tavlarides AM, Ames SC, Thiel DD, et al. Baseline and follow-up association of the MAX-PC in men with newly diagnosed prostate cancer. Psycho-Oncology. 2015;24:451–7.

    Article  PubMed  Google Scholar 

  34. Heck MM, Kron M, Gschwend JE, et al. Effect of family history on outcome in German patients treated with radical prostatectomy for clinically localised prostate cancer. Eur J Cancer. 2012;48:1312–7.

    Article  PubMed  Google Scholar 

  35. Lehmann C, Mehnert A, Schulte T, et al. Erfassung krebs-und behandlungsspezifischer Ängste bei Prostatakrebspatienten in der Rehabilitation: Der Memorial Angst-Fragebogen für Prostatakrebs (MAX-PC). Praxis Klinische Verhaltensmedizin und Rehabilitation. 2006;19:345–52.

    Google Scholar 

  36. Mehnert A, Lehmann C, Schulte T, et al. Presence of symptom distress and prostate cancer-related anxiety in patients at the beginning of cancer rehabilitation. Onkologie. 2007;30:551–6.

    PubMed  Google Scholar 

  37. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.

    Article  CAS  PubMed  Google Scholar 

  38. Kroenke K, Spitzer RL, Williams JB, et al. An ultra-brief screening scale for anxiety and depression: the PHQ–4. Psychosomatics. 2009;50:613–21.

    PubMed  Google Scholar 

  39. Löwe B, Wahl I, Rose M, et al. A 4-item measure of depression and anxiety: validation and standardization of the Patient Health Questionnaire-4 (PHQ-4) in the general population. J Affect Disord. 2010;122:86–95.

    Article  PubMed  Google Scholar 

  40. Lamers RE, Cuypers M, Husson O, et al. Patients are dissatisfied with information provision: perceived information provision and quality of life in prostate cancer patients. Psycho-Oncology. 2016;25:633–40.

    Article  PubMed  Google Scholar 

  41. Violan C, Foguet-Boreu Q, Flores-Mateo G, et al. Prevalence, determinants and patterns of multimorbidity in primary care: a systematic review of observational studies. PLoS One. 2014;9:e102149.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Vissers PA, Thong MS, Pouwer F, et al. The impact of comorbidity on health-related quality of life among cancer survivors: analyses of data from the PROFILES registry. J Cancer Surviv. 2013;7:602–13.

    Article  CAS  PubMed  Google Scholar 

  43. Drummond FJ, Kinnear H, O’Leary E, et al. Long-term health-related quality of life of prostate cancer survivors vary by primary treatment. Results from the PiCTure (Prostate Cancer Treatment, your experience) study. J Cancer Surviv. 2015;9:361–72.

    Article  PubMed  Google Scholar 

  44. Banks E, Byles JE, Gibson RE, et al. Is psychological distress in people living with cancer related to the fact of diagnosis, current treatment or level of disability? Findings from a large Australian study. Med J Aust. 2010;193(5 Suppl):S62–7.

    PubMed  Google Scholar 

  45. Roth A, Passik S. Anxiety in men with prostate cancer may interfere with effective management of the disease. Primary Care Cancer. 1996;16:30.

    Google Scholar 

  46. Lofters A, Juffs HG, Pond GR, et al. “PSA-itis”: knowledge of serum prostate specific antigen and other causes of anxiety in men with metastatic prostate cancer. J Urol. 2002;168:2516–20.

    Article  PubMed  Google Scholar 

  47. Hillen MA, de Haes HC, Smets EM. Cancer patients’ trust in their physician—a review. Psycho-Oncology. 2011;20:227–41.

    Article  PubMed  Google Scholar 

  48. Albright F, Stephenson RA, Agarwal N, et al. Prostate cancer risk prediction based on complete prostate cancer family history. Prostate. 2015;75:390–8.

    Article  PubMed  Google Scholar 

  49. Spencer BA, Babey SH, Etzioni DA, et al. A population-based survey of prostate-specific antigen testing among California men at higher risk for prostate carcinoma. Cancer. 2006;106:765–74.

    Article  PubMed  Google Scholar 

  50. Meiser B, Cowan R, Costello A, et al. Prostate cancer screening in men with a family history of prostate cancer: the role of partners in influencing men’s screening uptake. Urology. 2007;70:738–42.

    Article  PubMed  Google Scholar 

  51. Cohen L, Fouladi RT, Babaian RJ, et al. Cancer worry is associated with abnormal prostate-specific antigen levels in men participating in a community screening program. Cancer Epidemiol Biomark Prev. 2003;12:610–7.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany

    Valentin H. Meissner, Kathleen Herkommer & Jürgen E. Gschwend

  2. Department of Psychosomatic Medicine and Psychotherapy, Klinikum rechts der Isar, Technical University of Munich, Langerstr. 3, 81675, Munich, Germany

    Birgitt Marten-Mittag & Andreas Dinkel

Authors
  1. Valentin H. Meissner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kathleen Herkommer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Birgitt Marten-Mittag
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jürgen E. Gschwend
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Andreas Dinkel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andreas Dinkel.

Ethics declarations

Funding

None.

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in this study were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Meissner, V.H., Herkommer, K., Marten-Mittag, B. et al. Prostate cancer-related anxiety in long-term survivors after radical prostatectomy. J Cancer Surviv 11, 800–807 (2017). https://doi.org/10.1007/s11764-017-0619-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11764-017-0619-y

Keywords

Search

Navigation